by MM360 Staff | Jun 22, 2021 | Myeloma News
Source: Pharmacy Times articles Pharmacists can educate patients about a pair of new treatment options for multiple myeloma approved by the FDA in March 2021. Read More
by MM360 Staff | Jun 18, 2021 | Myeloma News
Here are the top 10 journal articles from the week of June 14, 2021 as selected by the MYELOMA360 staff. Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple...
by Sabrina Ahle | Jun 14, 2021 | Myeloma News
Source: Multiple Myeloma – ASH Clinical News Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple myeloma (MM) who have received at least...
by Sabrina Ahle | Jun 14, 2021 | Myeloma News
Source: Multiple Myeloma – ASH Clinical News Isatuximab-irfc, in combination with carfilzomib and dexamethasone (Isa-Kd), was approved by the U.S. Food and Drug Administration (FDA) on March 31, 2021 for the treatment of adults with relapsed or refractory multiple...
by Sabrina Ahle | Jun 14, 2021 | Myeloma News
Source: Multiple Myeloma – ASH Clinical News The addition of the anti-SLAMF7 antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and maintenance did not improve outcomes for patients with previously untreated high-risk multiple myeloma...
